Drug Combination Details
General Information of the Combination (ID: C85215) | |||||
---|---|---|---|---|---|
Name | Cyclopamine | + | Docetaxel + Gefitinib | ||
Click to Show/Hide the Each NP or Drug Information of This Combination | |||||
Name | Cyclopamine NP Info | Drug Info | |||
Structure | |||||
Name | Drug Info | ||||
Structure | |||||
Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
|
In-vitro Model | LNCaP | CVCL_0395 | Prostate carcinoma | Homo sapiens | ||
DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | |||
PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Combined use of inhibitors of EGF-EGFR and hedgehog signaling with docetaxel could represent a more promising strategy for treatment in patients with metastatic and androgen-independent prostate cancer. |